Loading Events

« All Events

  • This event has passed.

ESG in Life Sciences: The Current and Future State – Hosted by CohnReznick

November 17 @ 1:00 pm - 2:00 pm

ESG has become increasingly more important for all stakeholders in the life science industry. As such, organizations are taking inventory of the current state of ESG programs, and are developing new strategies and roadmaps to create safer products to enhance the patient experience and journey. Organizations are focusing on quality beyond compliance, enhancing reporting to promote improved transparency across the broad spectrum of stakeholders, and are strategizing on ways to engage underserved communities through clinical trial programs; all of which fold into the three pillars of ESG. Comprehension of the maturity of an organization’s ESG program is imperative to developing a robust future state roadmap and strategy to meet the needs of stakeholders.

A strong and well-documented ESG strategy and program is imperative to the future state of the life science industry as a whole. Please join members of CohnReznick’s ESG Global Consulting Services Advisory team for a live discussion to better understand the current state of ESG and hear our take on defining the future state of ESG in life sciences.

This live discussion will focus on the following:

Understanding the current state of ESG in MedTech and Pharma

~ The three pillars of ESG

~ Baseline reporting methodologies used by MedTech and Pharma companies

~ External and internal opportunities, challenges and trends

Future state of ESG in MedTech and Pharma

~ Ethics and compliance considerations

~ ESG program maturity

-Navigating the ESG journey

-Understanding your stakeholders (patients, employees, regulators, shareholders, and suppliers)

-Finding value and value creation through ESG maturity

-Mitigating future risks through the development of an ESG program

Speakers:

Maurice Crescenzi, Principal

Ben McGovern, Senior Manager

Nirmal Srinivasan, Senior Manager

Vishnu Dwadasi, Director of Manufacturing, Asshvattha Therapeutics

ESG has become increasingly more important for all stakeholders in the life science industry. As such, organizations are taking inventory of the current state of ESG programs, and are developing new strategies and roadmaps to create safer products to enhance the patient experience and journey. Organizations are focusing on quality beyond compliance, enhancing reporting to promote improved transparency across the broad spectrum of stakeholders, and are strategizing on ways to engage underserved communities through clinical trial programs; all of which fold into the three pillars of ESG. Comprehension of the maturity of an organization’s ESG program is imperative to developing a robust future state roadmap and strategy to meet the needs of stakeholders.

A strong and well-documented ESG strategy and program is imperative to the future state of the life science industry as a whole. Please join members of CohnReznick’s ESG Global Consulting Services Advisory team for a live discussion to better understand the current state of ESG and hear our take on defining the future state of ESG in life sciences.

This live discussion will focus on the following:

Understanding the current state of ESG in MedTech and Pharma

~ The three pillars of ESG

~ Baseline reporting methodologies used by MedTech and Pharma companies

~ External and internal opportunities, challenges and trends

Future state of ESG in MedTech and Pharma

~ Ethics and compliance considerations

~ ESG program maturity

-Navigating the ESG journey

-Understanding your stakeholders (patients, employees, regulators, shareholders, and suppliers)

-Finding value and value creation through ESG maturity

-Mitigating future risks through the development of an ESG program

Speakers:

Maurice Crescenzi, Principal

Ben McGovern, Senior Manager

Nirmal Srinivasan, Senior Manager

Vishnu Dwadasi, Director of Manufacturing, Asshvattha Therapeutics